Efficacy of GLP-1RA according to Type 2 Diabetes Phenotypes-A Monocentric Retrospective Study

被引：0
|
作者：
Caruso, Irene
Giordano, Fiorella
Di Gioia, Ludovico
Matichecchia, Immacolata I.
Cignarelli, Angelo
Sorice, Gian Pio
Perrini, Sebastio
Natalicchio, Annalisa
Laviola, Luigi
Giorgino, Francesco
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-783-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
783-P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events
    Meiring, S.
    Busch, C. B. E.
    van Baar, A. C. G.
    Hemke, R.
    Holleman, F.
    Nieuwdorp, M.
    Bergman, J. J. G. H. M.
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [42] Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?
    Bai, Shuzhen
    Lin, Chu
    Jiao, Ruoyang
    Cai, Xiaoling
    Hu, Suiyuan
    Lv, Fang
    Yang, Wenjia
    Zhu, Xingyun
    Ji, Linong
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2023, 109 : 79 - 88
  • [43] Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events
    S. Meiring
    C. B. E. Busch
    A. C. G. van Baar
    R. Hemke
    F. Holleman
    M. Nieuwdorp
    J. J. G. H. M. Bergman
    Cardiovascular Diabetology, 21
  • [44] Impact of GLP-1RA on the Risk of Adverse Liver Outcomes Among Patients With Alcohol-Associated Liver Disease and Type 2 Diabetes
    Rashid, Zayed
    Woldesenbet, Selamawit
    Khalil, Mujtaba
    Iyer, Sidharth
    Khan, Muhammad Muntazir Mehdi
    Altaf, Abdullah
    Munir, Muhammad Musaab
    Catalano, Giovanni
    Mumtaz, Khalid
    Pawlik, Timothy M.
    LIVER INTERNATIONAL, 2025, 45 (04)
  • [45] Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
    Koike, Masao
    Saito, Hitoki
    Kohno, Genta
    Takubo, Masahiro
    Watanabe, Kentaro
    Ishihara, Hisamitsu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21)
  • [46] ATGC-300, drug candidates for type 2 diabetes based on novel hybrid IgG fusion protein combined with GLP-1RA
    Kim, H.
    Choi, D.
    Lee, J.
    Jung, Y.
    Lee, W.
    Ji, H.
    Lee, J.
    Lee, H.
    Jang, S.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S242 - S243
  • [47] Response to: Impact of GLP-1RA on Adverse Liver Outcomes Among Patients With Alcohol-Associated Liver Disease and Type 2 Diabetes
    Rashid, Zayed
    Khalil, Mujtaba
    Pawlik, Timothy M.
    LIVER INTERNATIONAL, 2025, 45 (04)
  • [48] Empagliflozin versus DPP4i or GLP-1RA for the risk of nephrolithiasis in patients with type 2 diabetes: Research letter from the EMPRISE cohort study
    Tesfaye, Helen
    Paik, Julie M.
    Zakoul, Heidi
    Schmedt, Niklas
    Wexler, Deborah J.
    Patorno, Elisabetta
    DIABETES OBESITY & METABOLISM, 2025,
  • [49] Patient-Reported Outcomes following Initiation of Glucagon-Like Peptide-1 Receptor AgonistS (GLP-1RA) in PatientS with Type 2 Diabetes-PROGRESS-DIABETES Study
    Brown, Ruth E.
    Abitbol, Alexander
    Bajaj, Harpreet S.
    Khandwala, Hasnain
    Goldenberg, Ronald
    Abdel-Salam, Suzan
    Aronson, Ronnie
    DIABETES, 2018, 67
  • [50] GLP-1 RA and Risk of Malignancy in Patients with Type 2 Diabetes
    Ishola, Faidat A.
    Pike, C. William
    Kim, Sun H.
    DIABETES, 2024, 73
12345